Please login to the form below

Not currently logged in
Email:
Password:

BIA elects six new board members

Biotech trade body adds representatives from MedImmune, J&J and more

BIA J and J Patrick VerheyenUK trade body the BioIndustry Association (BIA) has elected six new members to its board.

They comprise senior figures from different member companies of the organisation, which represents the biotech industry in the UK.

The list of new members includes Patrick Verheyen (pictured right), head of Johnson & Johnson's innovation centre in London; Jane Osbourn of AstraZeneca subsidiary MedImmune; and Kevin Cox, CEO of imaging firm Imanova.

The remaining new appointments are Stephen Taylor of Fujifilm Diosynth Biotechnologies; Donna Hackett, director of life sciences consultancy firm KDH BioManagement; and Tim Watts, chief financial officer of Oxford BioMedica.

They will all serve from January 1, 2014, for term of three years.

The BIA also announced several returning board members, including John Brown of Vectura Group and Ian Tomlinson, senior VP of worldwide business development and biopharma research at GlaxoSmithKline.

“The appointees are recognised leaders of our industry and I look forward to working with them to help the BIA meet the needs of the bioscience sector in Europe's strongest bioscience cluster,” said Edward Hodgkin, BIA chairman.

15th October 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics